The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isn't the intention, these filings to a certain extent level the playing field for ordinary investors. The latest round of 13F […]...
Taking the term penny stock to a whole new level, we have Seanergy Maritime (SHIP). Shares are going for $0.12 apiece following another year of massive share price depreciation. The stock is down by 78% so far in 2020. Zoom out by five years and add in bouts of shareholder dilution, and the stock is only 0.25% away from a 100% decline.However, not all hope is lost. In fact, Maxim analyst Tate Sullivan remains firmly in the shipping company’s corner.Sullivan has a Buy rating on Seanergy based on his “outlook for SHIP to use recent equity proceeds to reduce and/or extend debt maturities, as well as our forecast for an eventual rebound in international shipping activity and higher rates.”Having said that, the decline in shipping rates means the price target is reduced from $0.40 to $0.30. Despite the trim, the potential upside from current levels is a lofty 120%. (To watch Sullivan’s track...
Gilead Sciences (GILD) isn’t a one-trick pony. While the news coverage has largely fixated on its potential COVID-19 treatment, remdesivir, the large-cap has an increasingly diverse pipeline.In addition to the headline grabbing remdesivir, Gilead is the biggest player in the HIV space, manufacturing what could become the best-selling HIV drug ever, Biktarvy.Having said that, Gilead has been expanding, and through a series of M&As, building an increasingly strong oncology portfolio. Following the addition of Kite in 2018 and the more recent acquisition of cancer-focused biotech Forty Seven, Gilead has just inked a deal with immuno-oncology player Arcus Biosciences. They have agreed to a 10-year partnership to develop next-generation cancer immunotherapies. Arcus will bring a number of immuno-oncology assets to the table, including a PD-1, anti-TIGIT, CD73 inhibitor, and a dual A2a/A2b antagonist, and in return, will receive $175 million upfront, a $200 million equity investment and R&D funding to the tune...
Posted by OFX AUD - Australian Dollar The Australian dollar made fresh multi-month highs on Thursday, extending gains despite a shift in equity markets. While global equity markets faltered Thursday as investors paused to take stock of recent gains, currencies enjoyed increasing demand for risk, driving commodity and growth sensitive units higher. … Continue reading "Australian dollar makes fresh multi-month highs as risk-on narrative continues"The post Australian dollar makes fresh multi-month highs as risk-on narrative continues appeared first on ....
There’s no doubt about it, Moderna’s (MRNA) profile has increased dramatically since the pandemic’s onset.The biotech name has climbed 206% higher this year, as investors have piled in with the hope that its COVID-19 vaccine candidate, mRNA-1273, might be the one to solve the coronavirus conundrum. Yet, it hasn’t all been positive news. Recently, questions have surfaced concerning the company’s sale of shares following the stock’s latest surge.Blocking out all of the noise, Oppenheimer analyst Hartag Singh recently attended Moderna’s virtual Science Day to get some visibility on the work going on behind the scenes. The 5-star analyst liked what he heard, to say the least.“Building on the last two Science Days, Moderna has kept a focus on strengthening its Research Platform science, with (1) increasing mRNA and encoded protein half-lives and stabilizing mRNA while avoiding double-stranded RNA impurities, (2) making a novel squaramide-based ionizable lipid (new LNP) to improve protein...
